Skip to main content
. 2022 Oct 13;127:10.48101/ujms.v127.8959. doi: 10.48101/ujms.v127.8959

Figure 2.

Figure 2

(a) T-cell reactivity against coronavirus disease 2019 (COVID-19) spike protein after SARS-CoV-2 BNT162b2 mRNA vaccine at 7–15 weeks after the second vaccine dose (Tcell1), 3 weeks (Tcell2), and 3 months after the third dose (Tcell3) in the 40 patients who remained during the entire study. (b) The individual change in T-cell reactivity against COVID-19 spike protein after SARS-CoV-2 BNT162b2 mRNA vaccine in 40 patients who remained during the entire study (‘spaghetti chart’).